Curis (NASDAQ:CRIS) Rating Reiterated by Cantor Fitzgerald

Curis (NASDAQ:CRISGet Rating)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Curis’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.80) EPS.

Curis Trading Up 1.1 %

Shares of CRIS stock opened at $0.79 on Wednesday. The firm has a fifty day moving average price of $1.02 and a 200 day moving average price of $1.26. The company has a market cap of $72.50 million, a P/E ratio of -1.28 and a beta of 2.64. Curis has a 12 month low of $0.70 and a 12 month high of $8.50.

Curis (NASDAQ:CRISGet Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). Curis had a negative net margin of 533.89% and a negative return on equity of 68.41%. During the same quarter in the prior year, the company earned ($0.12) earnings per share. On average, equities analysts forecast that Curis will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Curis

A number of institutional investors and hedge funds have recently bought and sold shares of CRIS. M28 Capital Management LP lifted its position in Curis by 62.6% in the first quarter. M28 Capital Management LP now owns 4,243,293 shares of the biotechnology company’s stock valued at $10,099,000 after acquiring an additional 1,634,442 shares during the last quarter. Nantahala Capital Management LLC lifted its position in Curis by 46.4% in the second quarter. Nantahala Capital Management LLC now owns 3,628,162 shares of the biotechnology company’s stock valued at $3,572,000 after acquiring an additional 1,149,897 shares during the last quarter. Renaissance Technologies LLC lifted its position in Curis by 81.5% in the second quarter. Renaissance Technologies LLC now owns 2,392,035 shares of the biotechnology company’s stock valued at $2,355,000 after acquiring an additional 1,073,835 shares during the last quarter. Walleye Capital LLC lifted its position in Curis by 3,036.1% in the first quarter. Walleye Capital LLC now owns 841,793 shares of the biotechnology company’s stock valued at $2,003,000 after acquiring an additional 814,951 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Curis by 465.8% in the first quarter. BNP Paribas Arbitrage SA now owns 446,469 shares of the biotechnology company’s stock valued at $1,063,000 after acquiring an additional 367,559 shares during the last quarter. 47.21% of the stock is owned by hedge funds and other institutional investors.

About Curis

(Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

See Also

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.